Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
AssigneeBionaut Pharmaceuticals, Inc.
InventorsMehran Khodadoust, Ajay Sharma
Life of this patent
Estimating the term…
Abstract
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells.
Claims24
A pharmaceutical formulation comprising a Na+/K+-ATPase inhibitor and an anti-cancer agent that induces an hypoxic stress response in tumor cells, formulated in a pharmaceutically acceptable excipient and suitable for use in humans to treat a neoplastic disorder.
A kit for treating a patient having a neoplastic disorder, comprising a Na+/K+-ATPase inhibitor and an anti-cancer agent that induces an hypoxic stress response in tumor cells, each formulated in premeasured doses for conjoint administration to a patient.
A method for treating a patient having a neoplastic disorder comprising administering to the patient an effective amount of a Na+/K+-ATPase inhibitor and an anti-cancer agent that induces an hypoxic stress response in tumor cells.
A method for promoting treatment of patients having a neoplastic disorder, comprising packaging, labeling and/or marketing a Na+/K+-ATPase inhibitor to be used in conjoint therapy for treating a patient having a neoplastic disorder with an anti-cancer agent that induces an hypoxic stress response in tumor cells.
A method for promoting treatment of patients having a neoplastic disorder, comprising packaging, labeling and/or marketing an anti-cancer agent that induces an hypoxic stress response in tumor cells to be used in conjoint therapy with a Na+/K+-ATPase inhibitor for treating a patient having a neoplastic disorder.
Dependencies are inferred from the claim text.